N-PORT filing recap · April 2025

What did ARK Genomic Revolution ETF buy in April 2025?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$946.28M

Positions

Estimated turnover

9.8%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Period in review

ARK Genomic Revolution ETF exited Accolade, Exact Sciences, and Repare Therapeutics during April. It added to Tempus Ai, Natera, Beam Therapeutics, Absci, and 10x Genomics, while trimming Adaptive Biotechnologies and Veeva Systems. The fund also made slight reductions across a broad set of holdings including Twist Bioscience, Guardant Health, Schrodinger, and Ionis Pharmaceuticals.

Increased positions

TEMTempus Ai, Inc.$79.10Mreported value+200.3K shares+15.1%CRSPCrispr Therapeutics AG$75.59Mreported value+107.4K shares+5.8%RXRXRecursion Pharmaceuticals, Inc.$65.84Mreported value+419.0K shares+3.7%NTRANatera, Inc.$56.55Mreported value+51.4K shares+15.9%

Reduced positions

TWSTTwist Bioscience Corporation$80.79Mreported value-14.7K shares-0.7%GHGuardant Health, Inc.$61.27Mreported value-99.2K shares-7.1%SDGRSchrodinger, Inc.$50.59Mreported value-168.9K shares-7.9%ADPTAdaptive Biotechnologies Corporation$43.84Mreported value-2.04M shares

Exited positions

ACCDAccolade Inc$19.12Mprior reported value-2.77M shares-100.0%EXASExact Sciences Corporation$4.30Mprior reported value-76.7K shares-100.0%RPTXRepare Therapeutics Inc.$2.37Mprior reported value-1.94M shares-100.0%